Business Wire

Global Bubble Tea Brand Continues Rapid International Growth

1.2.2021 11:00:00 EET | Business Wire | Press release

Share

Gong cha, one of the world’s most recognized Taiwanese bubble tea brands, continued its rapid expansion in 2020, opening new locations in multiple markets amid a challenging economic environment.

Last year, Gong cha opened 220 stores around the world, including 36 North American locations in Canada, Mexico and the U.S. The company now has a presence in 19 countries, with more than 1,400 locations. Building on this foundation, Gong cha will continue to grow in 2021, actively seeking additional franchisees across North America, Europe and Latin America. In the U.S., the company will be growing its presence in existing and new markets, including New York, Chicago, Portland, Seattle and Denver.

“We are excited by the ongoing demand for Gong cha, indicative of our product’s multicultural, international appeal,” said Einar Gustafsson, Gong cha CEO, Americas & Europe. “Younger demographic groups in particular are enthusiastically embracing bubble tea as their beverage of choice. As a leading brand in this fast-growing category, with a straightforward operating model, Gong cha offers a compelling franchise investment opportunity. We welcome new franchisees as we continue to expand our footprint in key markets around the world.”

Gong cha’s famous bubble tea is a premium milk tea infused with pearls (delicious chewy pearl-shaped tapioca), flavored with fruit and other toppings and usually served over ice. Gong cha’s top flavors include Pearl Milk Tea and Brown Sugar Milk Tea, and the company always offers innovative seasonal products, such as Mango Milk Foam Slush and Crème Brulee. Gong cha uses only the highest-quality, premium tea sourced from the finest tea estates of the famous Alesha region in Taiwan, serving freshly-brewed, customized bubble tea in 600 combinations, offering customers a new bubble tea experience with every visit. The company’s dedication to quality is the foundation of its promise to customers, helping to generate repeat business.

In addition to growing its market presence, Gong cha will also be expanding its bubble tea offerings in 2021, continuing the company’s well-known product innovation. This will include the February launch of the company’s Chocolate Lava Series, and the return of the popular Little Star Jelly Series. In April, the company will introduce a Heart Shaped Jelly Series of bubble tea, including Strawberry Honey Tea, Strawberry Milk Tea and Strawberry Smoothie flavors.

For more information on available territories and how to join the Gong cha franchise family, contact Mr. Gustafsson at einar.gustafsson@gong-cha.com.

About Gong cha Group

Founded in 2006, Gong cha is one of the most recognized Taiwanese tea brands in the world. Gong cha, which translates to “tribute tea for the emperor,” provides quality tea, products and services, sourcing ingredients from selected suppliers and offering customers freshly brewed tea. Gong cha’s leading product is its famous Taiwanese-style bubble tea, which is sweet milk tea infused with pearl-shaped tapioca. Gong cha also offers a variety of seasonal and specialty tea-based drinks. There are more than 1,400 Gong cha stores in 19 countries, including Taiwan, Korea, Japan, the Philippines, Vietnam, Malaysia, Singapore, Mexico, Australia, Canada, the United Kingdom and the United States. For more information, please visit www.gong-cha.com/en.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Philip Nunes
BackBay Communications
617-391-0792
phil.nunes@backbaycommunications.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA and chemotherapy regimen, demonstrating an improved OS hazard ratio, continued durable outcomes, and a generally manageable safety profile. These results reinforce findings from IA1, in which the regimen met the progression-free survival (PFS) and OS endpoints, wi

GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 10:00:00 EEST | Press release

GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release

Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye